Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole

Indian Journal of Medical Research

Volumn 123, Issue 4, 2006, Pages 517-524

  Dettmar, Peter W ^a   Hampson, F C ^a   Jain, A ^b   Choubey, S ^b   Little, S L ^a   Baxter, T ^a  

^a RECKITT BENCKISER   (United Kingdom)

^b Department of Histopathology   (India)

Author keywords

Alginate; Gastro oesophageal reflux; Omeprazole; Pharmacokinetic profile

Indexed keywords

ALGINIC ACID; GAVISCON; GAVISCON ADVANCE; OMEPRAZOLE; PLACEBO; POTASSIUM BICARBONATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADOLESCENT; ADULT; ALGINATES; ANTACIDS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; OMEPRAZOLE; PROTON PUMPS;

EID: 33745478142     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Washington N, Washington C, Wilson CG, Davis SS. The effect of inclusion of aluminium hydroxide in alginate-containing raft-forming antacids. Int J Pharmaceut 1986; 28 : 139-43.
2. Bennett CE, Hardy JG, Wilson CG. The influence of posture on the gastric emptying of antacids. Int J Pharmaceut 1984; 21 : 341-7.
3. May HA, Wilson CG, Hardy JG. Monitoring radiolabelled antacid preparations in the stomach. Int J Pharmaceut 1984; 19 : 169-76.
4. Washington N, Washington C, Wilson CG. Gastric distribution and residence time of two anti-reflux formulations. Int J Pharmaceut 1987; 39 : 163-71.
5. Burkitt V, Dettmar PW, Jolliffe IG, Sykes J. Evaluation of the barrier properties of UK alginate suspensions. Gut 2000; 47 (Suppl III) : A57.
6. Marciani L, Little SL, Coleman N, Young P, Taylor D, Snee J, et al. In vivo visualisation of Gaviscon alginate rafts using echo-planar magnetic resonance imaging. Gut 2001; 48 (Suppl I) : A36.
7. +) ATPase. Nature 1981; 290 : 159-61.
8. Regårdh C-G, Gabrielsson M, Hoffmann K-J, Lofberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol 1985; 20 (Suppl 108) : 79-94.
9. 14C] omeprazole in patients with liver cirrhosis. Clin Pharmacokinet 1993; 24 : 71-8.
10. 14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40 : 344-51.
11. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31 : 9-28.
12. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/140/98. EMEA 2001.
13. Hartmann M, Theiss U, Huber R, Lühman R, Bliesath H, Wurst W, et al. Twenty four hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10 : 359-66.
14. Nikiforova OV, Chistyakov VV, Shikh EV, Arzamastsev AP. Pharmacokinetics and bioavailability of gastrozole. Pharmaceut Chem J 1999; 33 : 173-6.
15. Farinha A, Bica A, Pais JP, Toscano MC, Tavares P. Bioequivalence evaluation of two omeprazole enteric-coated formulations in humans. Eur J Pharm Sci 1999; 7 : 311-5.
16. Pilbrant Å, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol 1985; 20 (Suppl 108) : 113-20.
17. Anderberg EK, Cullberg M, Långström G, Naesdal J, Rosén E. Bioequivalence between omeprazole MUPS® tablets and omeprazole capsules. Gastroenterology 1998; 114 : A56.
18. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytion hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16 : 214-5.
19. Sane RT, Ghadge JK, Jani AB, Vaidya AJ, Kotwal SS. Comparative evaluation of pharmacokinetic and bioequivalence study of omeprazole capsules in healthy Indian men. Indian Drugs 1992; 29 : 445-6.
20. Pritchard PJ, Yeomans ND, Mihaly GW, Jones DJ, Buckle PJ, Smallwood RA, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88 : 64-9.
21. Duvauchelle T, Millerioux L, Gualano V, Evene E, Alcaide A. Comparative bioavailability study of two oral omeprazole formulations after single and repeated administrations in healthy volunteers. Clin Drug Investig 1998; 16 : 141-9.
22. Sharma VK, Peyton B, Spears T, Raufman J P, Howden CW. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14 : 887-92.
23. Geus WP, Mathot RAA, Mulder PGH, Lamers CBHW. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2000; 14 : 1057-64.
24. Schaltenbrand R, Huber R, Cotoraci CA, Mascher H, Potthast H, Hole U. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule. Int J Clin Pharmacol Ther 2001; 39 : 453-9.
25. Tuynman HARE, Festen HPM, Meuwissen SGM. Pharmacokinetic studies with omeprazole: the effect of antacids on the bioavailability of omeprazole. Neth J Med 1986; 29 : 148.
26. Iwao K, Saitoh H, Takeda K, Azuumi Y, Takada M. Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules. Yakugaku Zasshi 1999; 119 : 221-8.